Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review
Amy H Huang1, Gin Yi Lee2, Chuan Angel Lu3
1Department of Internal Medicine, University of Connecticut School of Medicine, Farmington, CT.
JCO Oncology Practice
|December 15, 2025
Summary
EGFR inhibitor rechallenge improves outcomes in metastatic colorectal cancer (mCRC). Patients without RAS/RAF mutations and with longer treatment breaks benefit most from this strategy.
Area of Science:
- Oncology
- Medical Genetics
- Clinical Trials
Background:
- Clonal evolution drives resistance to epidermal growth factor receptor inhibitors (EGFRi) in metastatic colorectal cancer (mCRC).
- Discontinuation of EGFRi allows for decay of resistant subclones, enabling subsequent rechallenge.
- Understanding the efficacy of EGFRi rechallenge is crucial for optimizing treatment strategies in mCRC.
Purpose of the Study:
- To investigate the efficacy of epidermal growth factor receptor inhibitor (EGFRi) rechallenge in metastatic colorectal cancer (mCRC) through a meta-analysis.
- To compare the outcomes of EGFRi rechallenge with non-EGFRi systemic therapy in mCRC patients.
- To identify patient subgroups that may benefit more from EGFRi rechallenge.
Main Methods:
- A meta-analysis of clinical trials and observational studies on EGFRi rechallenge in mCRC.
- Inclusion of studies from PubMed and Embase up to December 8, 2024.
- Aggregation of hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) using Bayesian random-effects models; aggregation of objective response rates (ORRs) using meta-random-effects models.
Main Results:
- Twenty-nine studies were included, showing pooled median PFS of 3.83 months, median OS of 10.43 months, and ORR of 14.61%.
- EGFRi rechallenge significantly improved PFS (HR, 0.54) and numerically improved OS (HR, 0.71) compared to non-EGFRi therapy.
- Patients without detectable ctDNA RAS/RAF mutations and those with EGFRi-free intervals ≥4 months demonstrated significantly better outcomes.
Conclusions:
- EGFRi rechallenge offers significantly longer PFS, numerically longer OS, and clinically meaningful ORR in mCRC patients compared to non-EGFRi therapy.
- The benefit is particularly pronounced in patients with ctDNA RAS/RAF wild-type mCRC.
- EGFRi rechallenge is a viable strategy, especially when preceded by a sufficient treatment-free interval.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
9.2K
08:04In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
12.4K
Related Concept Videos
02:38Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K